Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP/p300 PROTAC Degrader for the Treatment of Advanced Prostate Cancer
Authors:
- 26 March 2024
- journal article
- research article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 67 (7) , 5351-5372
Abstract
CBP/p300 are critical transcriptional coactivators of the androgen receptor (AR) and are promising cancer therapeutic targets. Herein, we report the discovery of highly potent, selective, and orally bioavailable CBP/p300 degraders using the PROTAC technology with CBPD-409 being the most promising compound. CBPD-409 induces robust CBP/p300 degradation with DC50 0.2–0.4 nM and displays strong antiproliferative effects with IC50 1.2–2.0 nM in the VCaP, LNCaP, and 22Rv1 AR+ prostate cancer cell lines. It has a favorable pharmacokinetic profile and achieves 50% of oral bioavailability in mice. A single oral administration of CBPD-409 at 1 mg/kg achieves >95% depletion of CBP/p300 proteins in the VCaP tumor tissue. CBPD-409 exhibits strong tumor growth inhibition and is much more potent and efficacious than two CBP/p300 inhibitors CCS1477 and GNE-049 and the AR antagonist Enzalutamide. CBPD-409 is a promising CBP/p300 degrader for further extensive evaluations for the treatment of advanced prostate cancer and other types of human cancers.Keywords
Funding Information
- National Cancer Institute (P30 CA046592)
- Oncopia Therapeutics, Inc.
- Proteovant Therapeutics, Inc
This publication has 49 references indexed in Scilit:
- Targeted degradation of the enhancer lysine acetyltransferases CBP and p300Cell Chemical Biology, 2021
- Current development of CBP/p300 inhibitors in the last decadeEuropean Journal of Medicinal Chemistry, 2021
- PROTAC: A promising technology for cancer treatmentEuropean Journal of Medicinal Chemistry, 2020
- A Buchwald–Hartwig Protocol to Enable Rapid Linker Exploration of Cereblon E3‐Ligase PROTACs**Chemistry – A European Journal, 2020
- A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In VivoCancer Cell, 2019
- Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancerCancer Treatment Reviews, 2017
- Androgen receptor co-activators in the regulation of cellular events in prostate cancerWorld Journal of Urology, 2011
- Virtual Ligand Screening of the p300/CBP Histone Acetyltransferase: Identification of a Selective Small Molecule InhibitorChemistry & Biology, 2010
- The androgen receptor co‐activator CBP is up‐regulated following androgen withdrawal and is highly expressed in advanced prostate cancerThe Journal of Pathology, 2004
- Immunohistochemical study of androgen receptors in metastatic prostate cancer. Comparison of receptor content and response to hormonal therapyCancer, 1991